Moore Capital Management, LP Travere Therapeutics, Inc. Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $534,600 - $686,700	30,000 New	30,000 $674,000
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $2.42 Million - $3.03 Million	105,688 Added 122.84%	191,724 $4.72 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $1.32 Million - $1.89 Million	63,093 Added 275.0%	86,036 $2.09 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $541,684 - $702,055	22,943 New	22,943 $591,000

199

85.2M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.35B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.